A preliminary analysis and model of prostate injection distributions by Chowning, S.L. et al.
The Prostate 66:344 ^357 (2006)
APreliminaryAnalysis andModelof
Prostate InjectionDistributions
Scott L. Chowning,1* Robert C. Susil,1 Axel Krieger,3 Gabor Fichtinger,2,3,4
Louis L. Whitcomb,3,4 and Ergin Atalar1,2,5
1Departmentof Biomedical Engineering, JohnsHopkinsUniversity SchoolofMedicine,Baltimore,Maryland
2Departmentof Radiology, JohnsHopkinsUniversity SchoolofMedicine, Baltimore,Maryland
3DepartmentofMechanical Engineering, JohnsHopkinsUniversity, Baltimore,Maryland
4Departmentof Computer Science, JohnsHopkinsUniversity, Baltimore,Maryland
5Departmentof Electricaland Electronics Engineering,BilkentUniversity, Ankara,Turkey
PURPOSE. Understanding the internal dynamics of prostate injections, particularly injection
pattern distribution is a key step to developing new therapies for prostate disease that may be
best served with a direct injection approach. Due to excellent properties involving liquid
contrast agents, MRI can be used for targeting and monitoring of injections into organs and
tissues.
MATERIALSANDMETHODS. Eleven intraprostatic injections were performed in vivo with
canines using a custom transrectal guiding and imaging system for use in a standard 1.5 T MR
scanner. In addition, 25 injections were performed on excised cadaveric human prostates, using
a MedRad SpectrisTM injector system. MRI was used to guide the injections and monitor
intraparenchymal injection distribution.
RESULTS. T1 and T2-weighted MR images were correlated with histology to produce three-
dimensional data sets that can be used to analyze trends in injection patterns. This analysis
was used to develop strategies for injection prediction such as gadolinium preinjections and
diffusion-weighted imaging guidance. In addition, a rough model of prostate injections is
described, and a preliminary injection guide is developed that takes into account the individual
clinician’s goals for therapy.
CONCLUSIONS. MR visualization of injected therapeutic agents allows for prediction and
monitoring of drug distributions, possibly improving efficacy and reducing side effects. Injec-
tion analysis and modeling may be used to assist in optimizing clinical treatments that require or
would benefit from focal parenchymal injections into the prostate. Prostate 66: 344–357, 2006.
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INTRODUCTION
There are a number of clinical treatments that in-
volve direct intraparenchymal injection into various
organs and tissues [1–4]. New treatments are being
studied for prostate interventions, including injections
for benign prostate hypertrophy (BPH) and prostate
cancer [5]. Recently, such approaches have been
studied using endorectal and transperineal routes,
usually under ultrasound guidance, although MR is
beginning to see use as a possible imaging method for
prostatic injections [6]. In the case of BPH, ethanol
ablation has been studied as a possible therapy [7]. For
prostate cancer applications, new treatment techniques
are being developed which include immune system
stimulation [8], viral [9,10], genetic [11], and radiosensi-
tizing techniques [12]. While some treatment agents can
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be applied via a systemic route, others require a maxi-
mum local concentration for effectiveness and there-
fore focal injection is desirable [13].
Despite the promise of local prostate injections, there
are several complicating factors that so far have hinder-
ed widespread clinical usage. One problem in parti-
cular that has plagued local tissue injections is the
faulty assumption that the chemical agent will be de-
livered to the same site at which it is injected. In
addition, leakage is found to be a major problem with
intraprostatic injections [6]. It is conceivable that many
of these problems may be minimized through a better
understanding of prostate injection distribution and
probability of failure modes.
With this goal in mind, several imaging modalities
have been used to guide and monitor injections, in-
cluding ultrasound and magnetic resonance imaging.
Although there are several other imaging methods for
visualizing injected drug agents [14–16], MR is super-
ior in terms of soft tissue contrast [17]. Contrast agents
have been used previously for prostate imaging under
trans-rectal ultrasound (TRUS) imaging guidance [18],
and contrast-enhanced MR is used here as a tool to
analyze, model, and predict liquid bulk flow inside the
prostate. The goals of this study are: (1) Use a pre-
viously designed and described [6] MR-guided trans-
rectal prostate injection and imaging system to analyze
in vivo canine prostate injections; (2) compare/contrast
prostate canine injection patterns with human prostate;
(3) demonstrate accurate agent distribution confirma-
tion via MR methods; (4) analyze leakage modes in the
prostate; (5) show that tissue structure is a rough pre-
dictor of bulk flow inside the prostate; (6) develop a
model for guiding prostate injection strategies.
METHODS
Canine Injection Procedures
An MR-guided, endorectal prostate imaging and
injection system that allows for precise needle place-
ment was employed for the canine portion of this study.
This device was designed for canine trials and served as
the prototype for a next-generation implementation in
human trials [19]. All animal protocols were reviewed
and approved by the Johns Hopkins Animal Care
and Use Committee. The canines, each weighing
approximately 25 kg were anesthetized with a bolus
injection of thiopental and maintained on 1% isoflurane
throughout the experiment. An IV catheter was placed
in the right jugular vein for fluid administration and a
Foley catheter was utilized to aid in stabilizing the
prostate and to define the position of the prostatic
urethra. The animals were placed prone on the scanner
table with the pelvis slightly elevated (10 cm) with a
5 inch surface coil on the anterior surface of the
abdomen at the level of the prostate. The rectal probe
contains a single-loop endorectal imaging coil, and
images were captured with contributions from both the
endorectal coil and the 5 inch surface coil.
In the first canine, a 30 mM solution of Gd-DTPA in
normal saline was injected at eight sites within the
prostate gland. Different volumes of contrast solution
(0.15, 0.3, or 0.6 ml) as well as different injection rates
(0.6–6 ml/min) were utilized. In all cases except for
one, injections were performed directly through the
hollow 18-G canula. In one case, injections were per-
formed though a 0.018-inch (26 G) diameter needle
manufactured from nitinol hypotubing. Because these
small-diameter hypotubing needles are so compliant,
they were inserted into the tissue through the hollow
canula (which was left in place) such that they emerged
3 mm past the canula tip. During injection, the flow
of the contrast solution was monitored using a high
flip-angle, RF-spoiled, gradient echo imaging sequence
(FSPGR, TE¼ 1.5 msec, TR¼ 6 msec, flip angle¼ 908,
BW¼þ/ 62.5 KHz, FOV¼ 16 cm, no slice selection,
256 160, 0.96 sec/image). The location of the inject-
ed solution was determined by comparing gradient
echo axial images acquired both before and after
the injection (FSPGR, TE¼ 2.0 msec, TR¼ 80 msec, flip
angle¼ 608, BW¼þ/ 31.25 kHz, FOV¼ 16 cm, slice
thickness¼ 3 mm, slice gap¼ 0.5 mm, 256 256,
NEX¼ 4, scan time 1:20).
In the second canine, an iterative method for pre-
dicting the distribution of an injected therapeutic agent
(here, ethanol) was considered. To detect potentially
dangerous injections before the ethanol was introduced
(i.e., those injections that could damage the urethra),
test injections at each targeted site were performed
using 0.1 ml of 30 mM gadolinium-DTPA in normal
saline. All injections were performed through 0.018-
inch diameter nitinol needles. The distribution of
this injected solution was visualized on T1-weighted
images (TE¼ 9.2 msec, TR¼ 700 msec, BW¼þ/
 31.25 kHz, ETL¼ 4, FOV¼ 16 cm, slice thickness¼
3 mm, slice gap¼ 0.5 mm, 256 256, NEX¼ 4, scan
time¼ 3:00). Then, if the injection pattern was localized
and did not involve the urethra, 0.2 ml of dehydrated
ethanol was injected for tissue ablation. Following the
study and animal sacrifice, the prostate was removed,
fixed in formalin, and sectioned axially such that tissue
lesions could be correlated with the MR images.
Human Injection Procedures
A total of 13 fresh excised cadaveric human prostates
were removed surgically from the anatomy lab at the
Maryland State Anatomy Board with approval from
the Johns Hopkins University School of Medicine
Biosafety Officer and the Director of the Anatomy
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Board. Twelve of the prostates were kept in 0.9%
isosaline solution and refrigerated for a maximum of
24 hr before the imaging experiments. One prostate was
immediately placed in a 10% formalin solution for 48 hr
to achieve fixation. 0.5 ml of Gd-DTPA was added with
9.5 ml of each of four dyes—black, blue, green, and
red—to produce a 5% Gd-DTPA-dye solution.
For each prostate, up to four injection sites were
chosen, at different superior/inferior positions within
the prostate and targeting different anatomical bound-
aries within it (transition zone (TZ), peripheral zone
(PZ)). Since the human prostates were ex vivo, the
injection needle was placed by hand, and position
confirmed by T2 weighted MR. Each of the human
prostates were positioned with the urethra colinear
with the longitudinal axis of the MR bore, with the
posterior portion of the gland facing upwards.
This setup is close to the anatomical position of a
patient laying prone in the MR scanner, which is the
typical patient position for endorectal coil experiments
in vivo.
In the first set of experiments, injections were
performed on a formalin-fixed human prostate. To test
the effect of chemical fixation on prostate injections, we
injected three times into this fixed prostate at various
anatomical positions. We observed the flow of contrast
with MR guidance and then sectioned the gland for
histology analysis. Another set of trials was aimed at
analyzing leakage modes in the human prostate. Using
a fixed volume and flow rate of 1 ml, and 0.1 ml/sec,
respectively, ten separate injections were performed.
Of those ten injections, seven could be explicitly loca-
lized to either the TZ or PZ. The volume of contrast in
the parenchyma, as well as contrast seen in the urethra
or leakage out of the capsule was approximated on the
MR images using a contour tool. The contour tool gives
a measure of area covered, and then the total volume
was calculated by summing the areas found across all
the slices. We reported the numbers in terms of a
percentage volume distribution (numbers rounded to
nearest 10%).
To get a better understanding of how flow rate and
total volume affect injectant dispersion, we performed
16 injections and measured contrast dispersion with
MR guidance. In the first trial, we kept the flow rate and
total volume injected constant at 0.1 ml/sec and 1 ml
(N¼ 8). In the second trial, we increased the total
volume injected by 100% and held the flow rate
constant (N¼ 4). In a third trial, we kept the total
volume injected constant and changed the flow rate
from 0.1 ml/sec to 0.2 ml/sec (N¼ 4).
Before each injection, the following image sequences
were acquired in all three planes: (1) T1 weighted
RF-spoiled gradient echo (FSPGR, TE¼ 2.8 msec,
TR¼ 85 msec, flip angle¼ 608, BW¼þ/ 31.25 kHz,
FOV¼ 16 cm, 256 256, slice thickness¼ 3 mm, slice
gap¼ 0.5 mm, NEX¼ 4, scan time¼ 2:10); (2) T2
weighted fast spin echo (TE¼ 60 msec, TR¼ 5500 msec,
BW¼þ/ 15.6 kHz, ETL¼ 4, FOV¼ 16 cm, 256 256,
slice thickness¼ 3 mm, slice gap¼ 0.5 mm, scan time¼
5:20); and (3) T2 Diffusion-weighted images using
the General ElectricTM-developed DWI propeller se-
quence (TE¼ 100 msec, TR¼ 5,000 msec, ETL¼ 16,
b¼ 1,000 sec/mm2, 256 256, slice thickness¼ 3 mm,
slice gap¼ 0 mm, scan time¼ 7:00). The diffusion
weighted images were postprocessed using a General
Electric Signa LXTM console computer into three image
sets including a baseline unweighted set, an apparent
diffusion coefficient (ADC) map and an exponentially
weighted ADC map. All diffusion-weighted images
were acquired in the axial plane only. A standard
General ElectricTM head coil was used in all human
prostate injection experiments. A MedRad Spectris MR
Injection SystemTM was used for each injection (except
the formalin fixed prostate experiments, see Results for
reasoning/details). During the injection, a high flip
angle RF-spoiled fast gradient echo sequence (FSPGR,
TE¼ 1.5 msec, TR¼ 6 msec, flip angle¼ 908, BW¼þ/
 62.5 kHz, FOV¼ 16 cm, 256 160, 1 sec/image) was
used to monitor the real-time distribution of the
injected contrast agent. Afterwards, the same T1 and
T2 image sets described above were re-acquired to
show pre-and post-contrast images. After each imaging
experiment, the prostate was stored in 10% formalin
solution for 3 days, after which it was removed and




In the first canine, a series of eight transrectal in-
traprostatic needle placements and injections were
performed. During each injection, a high-flip-angle,
RF-spoiled, gradient-echo acquisition was run to visu-
alize the agent’s distribution. Dynamic images ac-
quired during five of the injections are shown in
Figs. 1–4. Each figure shows a sagittal scout along with
individual frames from the time-series images. In the
majority of cases, much of the solution does not stay
within the tissue but rather, leaks into surrounding
structures. In Figure 1, the solution tracks superiorly
along the interface between the rectum and the
prostate. Figure 2 shows a case where the solution
gathered along the needle path, which is brightly
enhanced by the end of the injection. In two cases, the
injected solution stayed very concentrated within the
tissue (as seen in Fig. 3). In Figure 4, the solution
penetrated to the middle of the prostate and then
tracked up the urethra towards the bladder.
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Multiple-InjectionDistribution Patterns
in Canine Prostate
As prostate cancer is often considered to be a
multifocal disease, it may be desirable to deliver a
therapeutic agent to the entire gland. Therefore, we
examined the feasibility of covering large regions of
tissue in the prostate by performing multiple injec-
tions. The eight injections performed in the first canine
were all targeted within two axial planes; the first five
injections were performed in one plane and the last
Fig. 1. Canine Single-injectionTrials: Injected contrast solution
accumulating at the prostate-rectum interface. The white box in
the sagital scout image (leftpanel) shows the location of the time-
series images (fourrightpanels).0.3mlof 30mMGd-DTPAinnor-
mal saline was injected over 30 sec through the 18-G canula.The
solutioncanbe seen tracking superiorly along theprostate-rectum
interface (openarrows).Timesaregivenin seconds.
Fig. 2. Canine Single-InjectionTrials: Injected contrast solution
tracking along the needle path. 0.3 ml of 30 mMGd-DTPA solution
was injected over 30 sec through the18-G canula.Themajority of
the solution is visible along the needle path (open arrows), rather
thanat theneedle tip.Timesaregivenin seconds.
Fig. 3. Canine Single-InjectionTrials: Injected contrast solution
accumulating at the needle tip. 0.3 ml of 30 mMGd-DTPA solution
was injected over 5 sec through the 18-G canula. The solution is
visible as a singlebolus at theneedle tip (arrows).Times aregiven in
seconds.
Fig. 4. Canine Single-InjectionTrials: Injected contrast solution
tracking along the intraprostatic urethra. 0.3 ml of the Gd-DTPA
solutionwasinjectedover5sec throughthe0.018-inchdiameterniti-
nolneedle.Rather than accumulating at theneedle tip, the solution
tracksup theintraprostaticurethra (openarrows).
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three in another. The results of the first six injections
are shown in Figure 5. Note that despite the large
number of injections performed within this image
slice, there are sizable regions of tissue that show no
contrast enhancement. However, the results of the last
three injections, shown in Figure 6, are significantly
different. Despite the low number of injections,
almost all of the tissue within the image slice shows
enhancement.
GadoliniumPreinjections
In the second canine, the utility of performing gado-
linium solution preinjections, before the therapeutic
agent is injected, was examined. Injections at two sites
within the canine prostate are demonstrated. Following
accurate placement of the needle at the first target site
(Fig. 7A), the gadolinium solution was injected. At this
site, gadolinium tracks to the urethra, showing that
subsequent ethanol injection may injure this tissue
(Fig. 7B). No ethanol was injected and the tissue was
spared. Therefore, no tissue damage, only minor bleed-
ing at the needle track was seen on gross pathology
(Fig. 7C). At the second injection site, the needle was
accurately placed (Fig. 7D) and gadolinium injected.
The gadolinium stayed more localized within the pros-
tate tissue and away from the urethra (Fig. 7E). This
injection site was deemed safe and subsequently, 0.2 ml
of ethanol was injected. The region of tissue damage, as
seen on gross pathology (Fig. 7F), correlates well with
the distribution of gadolinium on the T1-weighted
images.
HumanVersus Canine Prostate
Although the canine prostate is a widely used
model of the human prostate, injection experiments
reveal differences in tissue structure that affect
Fig. 5. Canine Multiple-InjectionTrials: Incomplete tissue enhancement.Five contrast boluses (all 0.3 ml except for the fourth, whichwas
0.6 ml) were injected over 30 sec (60 sec for the fourth bolus). Injection sites are indicated by thewhite circles.Despite the large number of
injections, amajorityof the tissuein thisimageplaneisnotenhanced.
Fig. 6. CanineMultiple-InjectionTrials:Completetissueenhance-
ment. Three boluses of Gd-DTPA solution (0.15, 0.3, and 0.3 ml,
respectively)wereinjectedover5seceach.Despite thelownumber
of injections, strong enhancement of the whole tissue plane is
achieved.
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intraparenchymal liquid distribution. From an axial
perspective, the canine prostate has a wedge-shaped
pattern of glandular units separated by connective
tissue, similar in structure to an orange. The human
prostate has a more complex structure, with ducts that
run from the periphery of the gland and spiral towards
the urethra on the posterior side. In general, the canine
prostate is symmetric with respect to the anterior/
posterior axis, whereas the human prostate is not. A
comparison of human and canine injections is shown in
Figure 8. Figure 8A shows an anterior injection pattern,
and Figure 8B/C show posterior injection patterns in
human prostates. Note that Figure 8D shows several
almost identical looking wedge shaped patterns from
multiple injections in the canine prostate. In the canine
model injecting into the anterior or posterior portion
of the gland gives the same distribution, whereas for
human prostates injecting in the anterior portion of the
gland gives a different distribution than the posterior
portion. These results are consistent with the anatomi-
cal structural differences between canine and human




A 0.018-inch diameter needle made from nitinol
hypotubing was placed in an excised human cadaveric
prostate and a volume of T1-weighted gradient echo
images were collected (Fig. 9, first column). Following
injection of 0.3 ml of Trypan blue tissue dye mixed with
30 mM Gd-DTPA, a second set of axial T1-weighted
images was acquired, allowing for clear visualization of
the injected solution (Fig. 9, second column). Tissue
sections corresponding to the imaged planes are shown
in Figure 9, third column. Note that there is good
agreement between the injectant dispersion patterns as
seen on MR images with the histology pictures taken
afterwards. This is evidence that MR guided injections




All injections into the fixed prostate required signi-
ficantly higher pressure to infuse the tissue, in fact the
pressure required was so large that it fell outside the
injector range of allowable fluid pressures. Therefore,
we had to deliver the injections by hand. The flow rate
was timed to be kept as close as possible to 0.1 ml/sec.
Figure 10 shows that the three formalin-fixed pros-
tate injections showed very poor tissue coverage com-
pared to the fresh prostates. Contrast enhancement was
limited to a vector-like pattern directly into the urethra.
Chemical fixation causes greatly increased tissue pres-
sure, which would explain the very limited tissue
Fig. 7. CanineGadoliniumPreinjectionTrials:Gd-DTPApreinjections canbeused topredictdrugdistributionpatterns.PanelA:The injec-
tionneedlewasaccuratelyplacedat the firstinjectionsite.PanelB:Gadoliniumsolutioninjectedat this site trackedto theurethra.Therefore,
noethanolwasinjectedhere.PanelC:No tissuenecrosisisvisibleongrosspathology(onlyminorbleedingat theneedle tip site).PanelD:The
injectionneedlewasaccuratelyplacedatthesecondinjectionsite.PanelE:Gadoliniumsolutioninjectedherestayedlocalized.Therefore,0.2ml
ofethanolwasinjected.Panel F:Tissuenecrosis isvisible ongrosspathologyandcorrelateswellwith thegadoliniuminjectionpattern. [Color
figurecanbeviewedin theonlineissue,whichis availableatwww.interscience.wiley.com.]
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distribution and higher fluid pressures required to
infiltrate the gland.
Real-TimeHuman Prostate Injection Images
Using the real-time MR sequence described in the
Methods, a ‘‘movie’’ comprised of 1-sec snapshots of
each injection was captured. Figure 11 shows an ex-
ample with a T2-weighted baseline image and several
snapshots after the injection at varying time intervals.
From this set of images, the contrast can be seen accu-
mulating at the needle tip and then gradually flowing
around the periphery of the TZ near the capsule to-
wards the PZ. The baseline image shows good contrast
between the TZ and PZ as a guide to distinguishing
these two different anatomical areas. Note that cover-
age in the TZ proper is poor, and that most of the
enhancement is seen in the capsular area, progres-
sing towards the PZ. This was a consistent theme in our
experiments; a TZ target covers only a small portion of
the TZ and most of the agent flows to the PZ.
Diffusion-Weighted Imaging
and InjectionCorrelation
Using the multiple spin echo T2 diffusion-weighted
sequence described previously, a diffusion map of the
axial plane of each human prostate was acquired.
Figure 11B shows the sum of the ADC and the expo-
nentially weighted ADC as a combination image. Note
the striking similarity between the tissue structure
shown in the baseline image (Fig. 11A) and the diffu-
sion image. As shown in the real-time data in Figure 11,
the injectant tends to distribute according to local tissue
structure, and this tissue structure has a correlation
with the diffusion-weighted data.
Leakage in theHuman Prostate
There was a correlation found between the injection
site and the probability of leakage. Leakage is defined
as contrast enhancement seen on MR in the urethra or
beyond the prostatic capsule (see Fig. 4 for an example).
Fig. 8. CanineversusHuman InjectionTrials: Canine injections displayuniformity whereas human injections show variance.PanelsA^C:
Humanprostate injections at variouspoints in the axial plane.Note the different shape of eachdistribution.Panel A is aT2weighted image in
which contrast appears dark.PanelD: Canineprostate injections showingmultiple injections in the same axialplane (arrowsmark injection
locations).Note theuniformwedge-shapeddistributions.
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Table I shows a breakdown of the injections that leaked.
A couple of observations arose from this data: (1) PZ
injections are more likely to leak via the urethra than TZ
injections; and (2) TZ injections are more likely to show
leakage through the prostatic capsule. Overall, 100% of
PZ injections showed some form of leakage, whereas
only 50% of the TZ targets showed leakage. Note that
the distances measured between PZ/TZ and leakage
points (urethra or capsule) lead to somewhat surprising
observations. The PZ-urethral distance was statistically
higher than the PZ-capsule distance, yet in spite of this
PZ-urethral leaks were much more common. On the
other hand, TZ-capsule distances averaged less than
TZ-urethral distances, and capsular leaks were found
to be more common. This suggests that bulk flow in the
PZ tends to be of a vector type nature that dominates in
one direction along the ducts. One possible explanation
for this phenomenon is based on the anatomical
structure of the duct coverage in the PZ. As the ducts
converge at the urethra, they become larger, and thus
can facilitate higher bulk flow in that direction. This
may create a tissue/fluid pressure gradient that
Fig. 9. Human InjectionTrials:Histology andmagnetic resonancemonitoring of distributions showclose agreement.First column: A 0.018-
inch diameter nitinol injection needle was placed by hand into the prostate, and T1-weighted gradient echo images were acquired. Second
column:Followinginjectionof 0.3mlof 30mMGd-DTPAmixedwithTrypanblue tissue dye (over 30 sec), a second setofT1-weightedgradient
echoimageswereacquired.Enhancementdue to thegadoliniumsolutionisclearly visible.Thirdcolumn:Blue stainedtissue.Seeningross tissue
sections of theprostate, correspondswellwith the enhancement seen inMR images. [Color figure canbeviewed in the online issue,which is
availableatwww.interscience.wiley.com.]
Fig. 10. HumanInjectionTrials:Threeinjectionsina formalin-fixedspecimen.Note theextremelypoorcoverageof the tissue.
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encourages flow in the direction of the urethra and
away from the capsule and lateral portions of the TZ.
Distribution Planes in theHuman Prostate
To get a better understanding of how drug distribu-
tion may differ in the three primary anatomical planes
(superior/inferior, anterior/posterior, and medial/
sagittal), we acquired images of all three major planes
after each injection. In the first set of experiments in
which both flow rate and total volume injected were
held constant, the dispersion of contrast relative to
the three major axes was measured and is shown in
Figure 12. Note that for constant flow rate and volume,
the dispersion amongst the axes showed little variation.
For the second set of trials in which volume was
increased by 100% with a fixed flow rate, the average
dispersion in the axial plane was relatively unchanged,
however the dispersion along the longitudinal axis
(superior to inferior direction) was increased substan-
tially. This further demonstrates the lack of correlation
between axial plane coverage and total volume injected
(compare Figs. 5 and 6). In the third set of trials with
varying flow rates and fixed total volume, the disper-
sion data sets were not statistically different (save for a
slight statistically significant variance in the anterior/
posterior distribution), although it is noteworthy that
the coverage was actually reduced in the increased
flow rate.
DISCUSSION
Intraprostatic injections, using dehydrated ethanol,
are currently being investigated as a minimally in-
vasive treatment for benign prostatic hypertrophy
(BPH) [20], which has a prevalence of 50% in men over
50 and greater than 80% in men over 80 [21]. When
injected into the prostate, ethanol induces cell lysis and
coagulation necrosis of arteries and veins, resulting in
tissue necrosis and subsequent shrinkage of the pros-
tate (reducing the obstructive symptoms caused by
BPH). Others have hypothesized that alcohol injections
reduce BPH symptoms by abolishing prostate cons-
triction (due to destruction of a-adrenergic receptors
Fig. 11. Human InjectionTrials: Diffusion-weighted and real-time MR images.Panel A:T2 weighted baseline image.Panel B:T2 diffusion
weightedimage (DWI).Other panels showreal time capture of injection (times are in seconds).Urethra is outlinedby thewhite circles.Note
theenlargedprostate,poorcoverageof transitionzone(TZ), andmotionofcontrast towardsperipheralzone.
352 Chowning et al.
in the tissue) [22]. However, side effects that have
plagued this treatment are inadvertent damage to the
external urethral sphincter, which is important for
urinary continence and stricture of the urethra [23].
This damage is caused by leakage of injected ethanol
into the urethra and periurethral tissue, which then
damages the endothelium and muscular sphincter,
resulting in stricture and/or incontinence. In light of
TABLE I. LeakageData in ExVivoHumanProstates















#1 8 8 Urethral 60 40 0
#2 10 8 Both 40 40 20
#3 14 8 Urethral 80 20 0
#4 11 5 Urethral 70 30 0
Transition zone injections
#1 4 6 Urethral 30 70 0
#2 13 6 Capsule 50 0 50
#3 19 6 Capsule 40 0 60
Average distance (mm) Average percent volumes
Peripheral zone to urethra 10.75 1.5 Peripheral zone-parenchymal 53%
Peripheral zone to capsule 7.25 0.9 Peripheral zone-urethral 33%
Transition zone to urethra 12 4.7 Transition zone-parenchyma 40%
Transition zone to capsule 6 0 Transition zone-capsular 37%
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the results seen in this study, the frequent side effects
following intraprostatic ethanol injections are not
surprising. When performing transrectal intraprostatic
injections, we observed significant leakage of contrast
solution in 8 of 11 cases in the canine model. A simpli-
stic model in which the injected agent stays localized at
the needle tip is insufficient.
MRI may be useful for improving the efficacy and
safety of these injections. First, through the use of real-
time projection imaging (Figs. 1–4), it is possible to
determine during the injection whether the agent is
staying localized at the target or rather, if it is leaking
into surrounding tissue. Therefore, failed injections
could be stopped early, conserving drug and pre-
venting damage to surrounding tissues. When a gado-
linium preinjection is delivered before the drug, this
approach allows for immediate determination of
whether the injection site is safe and therefore, whether
the therapeutic agent should be subsequently injected.
Second, if more precise visualization of the injected
agent is desired, T1-weighted images can be collected
to visualize the three-dimensional distribution of the
injected solution within the tissue (Figs. 7 and 8).
Clearly, intraprostratic injections performed with-
out direct imaging confirmation may not actually
deliver the therapeutic agent to a desired target. Given
the limited number of injections performed in this
study, it is difficult to suggest a definitive solution to
this problem. Nevertheless, several important mechan-
isms can be hypothesized based on these preliminary
results.
First, injection rate may play an important role in
determining the distribution of injected solutions. Fast
injection through the 18-G needle (Fig. 3) and the
hypotubing needles (Figs. 4 and 7) did not suffer
from ‘‘back-leakage’’ along the needle track. However,
another fast injection through the 18-G needle (0.3 ml in
5 sec) similar to Figure 4 did show some back-leakage
along the needle (results not shown). In these cases,
the velocity with which the solution exits the needle is
high (velocity is higher when using the hypotubing
needle because of its small cross-sectional area). The
resulting forward momentum may help to force the
solution into the tissue, resisting capillary forces that
would draw the liquid out along the needle path.
While this mechanism seems plausible, high injection
rates in the liver have been shown to increase leakage
rates [24].
Second, while high injection rate appears to reduce
back-leakage, it is also correlated with increased
leakage through the internal structures of the prostate
(as in Fig. 4, where solution tracked along the urethra).
If the solution is forced into the tissue, it will follow a
low resistance path, which in the prostate leads to the
urethra (the ductal structure of the canine and human
prostate is directed toward the intraprostatic urethra).
This is concerning in that high concentrations of a drug,
such as injected ethanol, may cause damage to the
urethra and associated sphincters and therefore lead to
either stricture or incontinence.
Third, as already alluded to, the underlying tissue
structure has a very significant impact on the distribu-
tion of an injected liquid agent. This effect is evident in
the canine prostate, which has a separated wedge-like
structure (similar to an orange cut in cross-section). In
Figures 5 and 6, this structure is clear after contrast
Fig. 12. HumanInjectionTrials: Injectantdispersionalongeachanatomicalaxis.A/P¼ anterior/posterior(fibromuscular zonetorectalwall),
M/S¼medial/sagittal (urethra to capsule), S/I¼ superior/inferior (base toapex).
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injection. Similarly, the injections performed in the ex-
cised cadaveric prostates follow the tissue structure of
the human prostate. For example, in Figure 8C, contrast
tracks along the course of secretary ducts within the
peripheral gland, which flow toward the midline of the
gland and the urethra [25].
Other factors which are likely to be important in-
clude the viscosity of the injected solution (highly
viscous solutions flow, and therefore leak, less easily),
the size of the injection needle (independent from in-
jection rate, smaller needles may reduce damage to the
tissue structure, and therefore reduce leakage), and the
volume of injected solution (smaller volume injections
will result in lower pressures and therefore, reduced
leakage flow). Further work is warranted to clarify the
relative important of each of these factors.
The present results showed only modest success
in reliably covering large regions of tissue with a small
number of injections. Our limited data suggest that
total volume injected has a poor correlation with
tissue coverage. Indeed, the canine prostate experi-
ments showed greater coverage when less total volume
was injected and more total injection sites were used.
Further work needs to be done to elucidate whether or
not this is a consistent phenomenon. While global
enhancement was achieved in Figure 6, it is important
to note that this enhancement was limited to the 3 mm-
thick slice shown (some enhancement of the neighbor-
ing slices was also seen). To cover the entire prostate,
better strategies—such as needles with multiple tips or
side ports—may be necessary.
To help predict the tissue distribution of a ther-
apeutic agent, a contrast preinjection strategy has been
proposed and demonstrated (Fig. 7). While this tech-
nique appears attractive, it relies on important assump-
tions. First, the distribution pattern of the therapeutic
agent must be similar to that of the preinjection; other-
wise, the preinjection will not yield useful information.
In the example using ethanol presented here, it ap-
pears that the injected ethanol has a more restricted
tissue distribution than the 30 mM Gd-DTPA solution
(compare Figure 7E, F). Therefore, just because the Gd-
DTPA solution tracked to the urethra in the first
injection (Fig. 7B), we cannot be sure that the ethanol
would have matched that distribution. Unequal dis-
tribution will likely be a problem for many agents,
unless the preinjected agent can match the molecular
size and chemical characteristics of the therapeutic
solution. However, as the initial distribution pattern
appears to be determined largely by bulk fluid flow,
matching characteristics such as viscosity may be
sufficient.
One key finding to future research methodology in
this area is that formalin-fixed human prostates give
profoundly different injection patterns than fresh pros-
tates. Since fresh prostates stored in isosaline solution
are assumed to be a better model of in vivo prostate
injections, it is important that all ex vivo modeling be
done on fresh not fixed specimens. Fresh ex vivo pros-
tate injections may differ from in vivo results, due to
many variables such as altered tissue compliance,
perfusion washout due to blood flow, and physiologi-
cal parameters not active in fixed specimens. Despite
the limitations of ex vivo work, we believe this is a
fundamental step on the road to in vivo testing. More
work is planned in the future with in vivo studies to
determine if injection patterns remain similar.
The leakage data in Table I show that PZ injections
have an extremely high probability of urethral leakage.
In fact, every single injection in the PZ showed some
urethral leak. Depending on the particular clinical
application this can be acceptable or not. For example,
in ethanol ablation therapy, leakage in the urethra
would be highly undesirable, due to possible damage
at the urethral sphincter. On the other hand, in the case
of an adenovirus vector used for prostate cancer treat-
ment, urethral leakage is not nearly as troublesome.
The nerve plexus that controls erectile function is
located outside the prostatic capsule, and some drug
agents such as certain chemotherapeutics may harm
these nerves; under this scenario minimizing capsular
leakage may take precedence over urethral leakage.
Capsular leakage was found to be not as common as
urethral leakage, although TZ targets do face a higher
probability of capsular leak. These observations sug-
gest that if avoiding urethral leak is a primary goal,
then PZ injections should be avoided, whereas if the
clinician is more concerned with capsular leaks and
can afford to risk urethral leakages, then the TZ is an
optimal injection target.
A preliminary injection model can be based on the
data in Figures 11 and 12. Generally, our experiments
showed that TZ targets showed reduced bulk flow
compared to the PZ targets, which has a good cor-
relation with the diffusion-weighted image presented
in Figure 11. In addition other studies have shown that
the TZ has a lower ADC on average compared to PZ
tissue [26], giving further credence to the hypothesis
that tissue structure and diffusion-weighted maps are
one predictor of injectant distribution. This suggests
that therapeutic targets in the TZ may require multiple
injection sites and/or a larger total volume injected.
Note that Figure 8C shows that a PZ injection to one
side of the prostate can result in coverage of both PZ
lobes. In our experiments, we found that it was rare for
TZ injections to penetrate bilaterally. This suggests that
bilateral coverage of PZ targets may be achieved with a
unilateral injection site, whereas bilateral TZ coverage
probably requires bilateral injection sites. It is noted
that larger total volume injected has relatively little
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effect on axial plane dispersion but does have a
sizable impact on longitudinal (coronal and sagittal
plane) dispersion (Fig. 12).
One final interesting observation regarding TZ
versus PZ injections is that a sufficiently large volume
delivered to the TZ can in some cases penetrate a good
portion of the ipsilateral PZ, whereas larger volumes
delivered to the PZ rarely cover the TZ and the excess
volume tends to either leak out the urethra or flow to
the bilateral PZ via the major ducts that converge with
the urethra at the verumontanum and at distributed
sites in the periurethral region. See Figures 8 and 9 for
examples of PZ and TZ distributions. Figure 9 shows an
example of a TZ injection, whereas Figure 8C shows a
PZ injection. More work needs to be done to have
sufficient statistical certainty of this phenomenon, but if
this holds up to further scrutiny it could be extremely
valuable as an injection-planning tool.
CONCLUSION
Although prostate injections are a desirable mini-
mally invasive procedure for some pathologies, this
modality is still under utilized due to failure modes
that can lead to complications, as well as uncertainty
regarding optimal injection techniques. This study at-
tempts to address some of these issues using the
advantages of MR imaging that elude traditional TRUS
imaging, such as excellent soft tissue contrast. Leakage
modes were demonstrated, including capsular back
leakage along the needle path and urethral leakage for
PZ targets. Drug agent distribution was analyzed in
three anatomical planes, and a preliminary guide to
injection planning was developed based on that data.
Dynamic imaging during the injection as well as T1-
weighted imaging after the injection allows for mon-
itoring of the solution’s distribution within and around
the prostate. Primarily, we have found that intrapro-
static injections often follow a complex distribution
within and around the prostate; leakage both within
and around the prostate was common. MR visualiza-
tion of injected agents may allow for prediction and
monitoring of drug distributions, improving efficacy,
and reducing treatment side effects. One strategy for
predicting drug distribution patterns, the use of a
contrast preinjection was suggested and demonstrated.
Taking into account the unique properties of the
prostate zones, as well as the prostate structure as a
whole, can serve as a preliminary guide to planning
injections. Further studies, taking advantage of the
ability of MRI to reveal tissue micro- and super-
structure, may allow for improved prediction of drug
distribution and therefore optimization of therapeutic
agent delivery.
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